Article Title
Atypical Hemolytic Uremic Syndrome: An Unusual Complication of Activated Prothrombin Complex Concentrate
Abstract
Abstract:
Atypical Hemolytic Uremic Syndrome (aHUS) is defined by thrombocytopenia, hemolytic anemia, and acute renal failure. FEIBA is a concentrate of inactivated and activated coagulation factors that has been classically used to establish hemostasis in those with hemophilia or acquired factor inhibitors. However, recently it has seen used off-label as an anticoagulant reversal therapy amongst the general population.
Herein, we report for the first time aHUS attributed to the administration of a single large dose of FEIBA for anticoagulation reversal treated with hemodialysis and four weekly doses of eculizumab to quell disease and achieve dialysis independence.